Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Res. 2019 Oct 7;79(23):5999–6009. doi: 10.1158/0008-5472.CAN-18-4108

Figure 6, ICAM-1 and T cells are needed for dysbiotic-induced tumor progression and TNF-α supplementation rescues T cell trafficking under dysbiotic conditions.

Figure 6,

(A) Tumor growth curves of B16-F10 melanoma in ICAM-1−/− mice with and without dysbiotic conditions. (B) Tumor growth rates of B16-F10 melanoma in immunocompetent (C57BL/6J) and T-cell impaired Foxn1−/− mice with and without dysbiotic conditions. (C) Tumor growth curves of B16-F10 melanoma during dysbiotic conditions with or without TNF-α supplementation (q3dx4; 120 μg/kg). (D) Quantification of ICAM-1 (CD54) expressing (CD45- CD31+) TEC and (E) tumor infiltrated CD3+ CD8+ T cells in B16-F10 tumors during dysbiotic conditions with or without TNF-α. Data presented as means ± SEM (n = 4 or 5 B16-F10 tumors per group). *P < 0.05, two-sided t-test. ns = not significant. Panel A: -▽- ICAM-1−/−, -▲- dysbiotic (Dys) ICAM-1−/−, and -◯- wild type (wt) mice; Panel C: -☐- dysbiotic (Dys) mice and -◼- dysbiotic mice supplemented with TNF-α (Dys + TNF-α)